Ultragenyx (RARE) Financials & Stock Activity Analysis

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE): Analyzing Key Financials and Recent Stock Activity

  • Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company, is dedicated to developing treatments for rare genetic diseases, strategically using inducement grants to attract and retain top talent.
  • Despite a recent insider stock sale, the analyst firm Cantor Fitzgerald maintained an "Overweight" rating on Ultragenyx Pharmaceutical Inc., signaling continued confidence in its market outlook.
  • Key financial metrics for Ultragenyx Pharmaceutical Inc. include a negative Price-to-Earnings (P/E) ratio of -3.86, a Price-to-Sales ratio of 3.44, and a robust current ratio of 2.02, indicating strong short-term liquidity.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a biopharmaceutical company. It focuses on developing and selling new treatments for serious rare and ultra-rare genetic diseases. The company aims to provide therapies for patients who have few or no other treatment options available to them.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) recently reported an inducement grant of 17,567 restricted stock units. These were given to 11 newly hired non-executive employees. This type of grant is a common tool companies use to attract and retain new talent, aligning employee interests with the company's long-term performance.

The awards were approved by the company's compensation committee. The stock units will vest over four years, with 25% becoming available each year. This is dependent on the employees staying with the company. In a separate transaction, a director, SULIMAN SHEHNAAZ, sold 5,740 shares for a total of $144,189.00.

Despite the insider sale, the analyst firm Cantor Fitzgerald maintained its "Overweight" rating on Ultragenyx Pharmaceutical Inc. The stock price was $23.37 at the time. The company's financial data shows a Price-to-Earnings (P/E) ratio of -3.86. A negative P/E ratio indicates that the company has had negative earnings over the past year.

Other financial metrics show a Price-to-Sales ratio of 3.44 and a negative Enterprise Value to Operating Cash Flow of -6.70. This suggests Ultragenyx Pharmaceutical Inc. is spending more cash on its operations than it generates. However, its current ratio is 2.02, showing it has enough short-term assets to cover its short-term liabilities.

About the Author
Rayan Ahmad

Market news and analyst rating coverage

Rayan Ahmad covers market news, analyst rating changes, and company developments for the FMP blog. His work focuses on summarizing price-target updates, earnings results, and broker actions into accessible, data-backed market updates.

Related

Financial data for every need

Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions — all accessible via API.

Create Free Account